CAR T–associated toxicities
| Acute phase (D0-30) . | Late phase (D30+) . |
|---|---|
| • CRS | • Persistent cytopenias |
| • Immune effector cell–associated neurotoxicity syndrome | • B-cell aplasia and hypogammaglobulinemia |
| • Cytopenias | • ?IVIG replacement |
| • Macrophage activation syndrome or hemophagocytic lymphohistiocytosis, is a very rare and severe form | • T-cell deficiency |
| • Disseminated intravascular coagulopathy | • Pneumocystis jirovecii pneumonia and varicella-zoster virus prophylaxis, other? |
| • Infection prophylaxis | |
| • B-cell aplasia and hypogammaglobulinemia | • Residual effects of acute toxicity |
| • Life threatening if not managed by expert multidisciplinary team | • Delayed CRS and neurotoxicity is rare but can occur. |
| • Tumor lysis is rare and probably varies by disease and disease burden. | • Impaired quality of life: fatigue, memory issues, not yet well described |
| Acute phase (D0-30) . | Late phase (D30+) . |
|---|---|
| • CRS | • Persistent cytopenias |
| • Immune effector cell–associated neurotoxicity syndrome | • B-cell aplasia and hypogammaglobulinemia |
| • Cytopenias | • ?IVIG replacement |
| • Macrophage activation syndrome or hemophagocytic lymphohistiocytosis, is a very rare and severe form | • T-cell deficiency |
| • Disseminated intravascular coagulopathy | • Pneumocystis jirovecii pneumonia and varicella-zoster virus prophylaxis, other? |
| • Infection prophylaxis | |
| • B-cell aplasia and hypogammaglobulinemia | • Residual effects of acute toxicity |
| • Life threatening if not managed by expert multidisciplinary team | • Delayed CRS and neurotoxicity is rare but can occur. |
| • Tumor lysis is rare and probably varies by disease and disease burden. | • Impaired quality of life: fatigue, memory issues, not yet well described |